Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap609.42M
Enterprise Value439.67M
CBIO
(NASDAQ)Crescent Biopharma, Inc.
$19.46-- (--)
Loading... - Market loading
Crescent Biopharma (CBIO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)51.29
Forward Price/Sales1.67
Price/Book (mrq)3.83
Price/Tangible Book (mrq)3.94
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue37.00
EV/Earnings-2.66
EV/EBITDA-2.65
EV/EBIT-2.63
EV/FCF-2.86
Stock Price
Current price, 52-week range, and moving averages
Current Price$19.96
1-Day Change-2.44%
52-Week High$27.41
52-Week Low$8.72
52-Week Change59.04%
YTD Change80.14%
1-Year Change63.21%
50-Day MA$16.87
200-Day MA$15.53
Avg Volume (30 day)257.78K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding30.53M
Book Value per Share$5.22
Net Cash per Share$5.56
FCF per Share$-5.03
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$32.50
Target Upside/Downside62.83%
Analyst ConsensusBuy
Analyst Count2
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin100.00%
EBITDA Margin (ttm)-1394.57%
EBIT Margin (ttm)-1408.52%
Operating Margin (ttm)-1417.74%
Pretax Margin (ttm)-1347.10%
Profit Margin (ttm)-1389.58%
FCF Margin (ttm)-1292.75%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-103.70%
Return on Assets (ttm)-90.35%
Return on Capital Employed (ttm)-101.92%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue11.88M
Gross Profit11.88M
Operating Income-168.47M
Pretax Income-160.08M
Net Income-165.12M
EBITDA-165.72M
EBIT-167.38M
Diluted EPS$-6.76
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-72.68M
Capital Expenditures80.94M
Free Cash Flow-153.62M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)182.76M
Cash & Securities (mrq)171.59M
Net Cash (mrq)169.75M
Net Cash per Share$5.56
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)1.84M
Working Capital (mrq)160.47M
Total Equity (mrq)159.23M
Book Value per Share$5.22
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)9.66
Quick Ratio (mrq)9.66
Debt/Equity (mrq)0.01
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Ex-Dividend DateJan 13, 2023
Pay DateJan 13, 2023
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-27.10%
FCF Yield-25.21%
Buyback Yield-29.33%
Total Shareholder Yield-29.33%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score10.01
Piotroski F-Score5/9
Frequently Asked Questions About Crescent Biopharma Statistics
What are the key financial metrics for CBIO?
Crescent Biopharma, Inc. (CBIO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is CBIO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Crescent Biopharma is overvalued or undervalued.
How do I read CBIO's profitability ratios?
Crescent Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do CBIO's debt ratios indicate?
The financial health section shows Crescent Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is CBIO's dividend analysis?
The dividend section covers Crescent Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.